Heavy Metal Poisoning - Pipeline Review, H2 2018

Date: October 16, 2018
Pages: 40
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H5048C1F434EN
Leaflet:

Download PDF Leaflet

Heavy Metal Poisoning - Pipeline Review, H2 2018
Heavy Metal Poisoning - Pipeline Review, H2 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Heavy Metal Poisoning - Pipeline Review, H2 2018, provides an overview of the Heavy Metal Poisoning (Toxicology) pipeline landscape.

Heavy metal poisoning is the accumulation of heavy metals, in toxic amounts, in the soft tissues of the body. Sources of toxicity can include environmental, water supply, industrial and hobbies. Symptoms include headaches, drowsiness, confusion, seizures, nausea, vomiting, abdominal cramps, tinnitus, goiter, anorexia and diarrhea. Treatment includes chelation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Heavy Metal Poisoning - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Heavy Metal Poisoning (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Heavy Metal Poisoning (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Heavy Metal Poisoning and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 4 respectively. Similarly, the Universities portfolio in IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Heavy Metal Poisoning (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Heavy Metal Poisoning (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Heavy Metal Poisoning (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Heavy Metal Poisoning (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Heavy Metal Poisoning (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Heavy Metal Poisoning (Toxicology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Heavy Metal Poisoning (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Heavy Metal Poisoning (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Global Markets Direct Report Coverage
Heavy Metal Poisoning - Overview
Heavy Metal Poisoning - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Heavy Metal Poisoning - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Heavy Metal Poisoning - Companies Involved in Therapeutics Development
DisperSol Technologies LLC
La Jolla Pharmaceutical Company
Medesis Pharma SA
PDX Pharmaceuticals LLC
Heavy Metal Poisoning - Drug Profiles
deferasirox - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
deferoxamine mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emeramide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hinokitiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJPC-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NU-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NU-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PDX-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Heavy Metal Poisoning - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Zn-DTPA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Heavy Metal Poisoning - Dormant Projects
Heavy Metal Poisoning - Discontinued Products
Heavy Metal Poisoning - Product Development Milestones
Featured News & Press Releases
May 17, 2018: La Jolla Pharmaceutical Company Announces LJPC-401 Presentations at 23rd Congress of the European Hematology Association
Mar 30, 2017: SRI International Receives U.S. FDA Clearance for Investigational New Drug Application Evaluating Novel Oral Treatment to Combat Radiation Exposure
Sep 11, 2015: La Jolla Pharmaceutical Company Receives Positive Opinion from European Orphan Committee for LJPC-401
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Heavy Metal Poisoning, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Heavy Metal Poisoning - Pipeline by DisperSol Technologies LLC, H2 2018
Heavy Metal Poisoning - Pipeline by La Jolla Pharmaceutical Company, H2 2018
Heavy Metal Poisoning - Pipeline by Medesis Pharma SA, H2 2018
Heavy Metal Poisoning - Pipeline by PDX Pharmaceuticals LLC, H2 2018
Heavy Metal Poisoning - Dormant Projects, H2 2018
Heavy Metal Poisoning - Discontinued Products, H2 2018

LIST OF FIGURES

Number of Products under Development for Heavy Metal Poisoning, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

DisperSol Technologies LLC
La Jolla Pharmaceutical Company
Medesis Pharma SA
PDX Pharmaceuticals LLC
Skip to top


Ask Your Question

Heavy Metal Poisoning - Pipeline Review, H2 2018
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: